GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Enzo Biochem Inc (NYSE:ENZ) » Definitions » YoY EPS Growth

Enzo Biochem (Enzo Biochem) YoY EPS Growth : 73.91% (As of Jan. 2024)


View and export this data going back to 1980. Start your Free Trial

What is Enzo Biochem YoY EPS Growth?

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months. Enzo Biochem's YoY EPS Growth for the quarter that ended in Jan. 2024 was 73.91%.

Enzo Biochem's Earnings per Share (Diluted) for the three months ended in Jan. 2024 was $-0.06.

Enzo Biochem YoY EPS Growth Historical Data

The historical data trend for Enzo Biochem's YoY EPS Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Enzo Biochem YoY EPS Growth Chart

Enzo Biochem Annual Data
Trend Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22 Jul23
YoY EPS Growth
Get a 7-Day Free Trial Premium Member Only Premium Member Only 122.73 -1,300.00 126.67 -337.50 207.89

Enzo Biochem Quarterly Data
Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23 Apr23 Jul23 Oct23 Jan24
YoY EPS Growth Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -360.00 -210.00 750.00 40.91 73.91

Enzo Biochem YoY EPS Growth Calculation

YoY EPS Growth is the percentage change of Earnings per Share (Diluted) over the past twelve months.

Enzo Biochem's YoY EPS Growth for the fiscal year that ended in Jul. 2023 is calculated as:

YoY EPS Growth (A: Jul. 2023 )
=(Earnings per Share (Diluted) (A: Jul. 2023 )-Earnings per Share (Diluted) (A: Jul. 2022 ))/ | Earnings per Share (Diluted) (A: Jul. 2022 ) |
=(0.41--0.38)/ | -0.38 |
=207.89 %

Enzo Biochem's YoY EPS Growth for the quarter that ended in Jan. 2024 is calculated as:

YoY EPS Growth (Q: Jan. 2024 )
=(Earnings per Share (Diluted) (Q: Jan. 2024 )-Earnings per Share (Diluted) (Q: Jan. 2023 )) / | Earnings per Share (Diluted) (Q: Jan. 2023 )) |
=(-0.06--0.23)/ | -0.23 |
=73.91 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enzo Biochem YoY EPS Growth Related Terms

Thank you for viewing the detailed overview of Enzo Biochem's YoY EPS Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

Enzo Biochem (Enzo Biochem) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Enzo Biochem Inc (NYSE:ENZ) » Definitions » YoY EPS Growth
Comparable Companies
NOTV VNRX BIOQ STIM PSNL PRE OCX MDXH TTOO XGN TMO DHR A IDXX IQV XSWX:LONN MTD ICLR WAT ILMN
Traded in Other Exchanges
EZB:Germany
Address
527 Madison Avenue, New York, NY, USA, 10022
Website
https://www.enzo.com
Enzo Biochem Inc is a bioscience company. The firm manufactures, develops and sell their proprietary solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians internationally. It focuses on delivering and applying its technology to produce products and services to allow its customers to meet their clinical needs. The company has Enzo clinical labs, Enzo life sciences, Enzo therapeutics operating segments. It derives the majority of its revenues from the Clinical lab's segment.
Executives
Steven J Pully director 9800 RICHMOND AVE, SUITE 700, HOUSTON TX 77042
James G. Wolf 10 percent owner 105, FLYWAY DRIVE, KIAWAH ISLAND SC 29455
Hamid Erfanian officer: Chief Executive Officer 527 MADISON AVENUE, NEW YORK NY 10022
Patricia Eckert officer: Interim CFO C/O ENZO BIOCHEM, INC., 81 EXECUTIVE BLVD, SUITE 3, FARMINGDALE NY 11735
Kara Cannon officer: Chief Operating Officer 527 MADISON AVE, NEW YORK NY 10022
Bradley Louis Radoff director 2727 KIRBY DRIVE, UNIT 29L, HOUSTON TX 77098
David Bench officer: CHIEF FINANCIAL OFFICER ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022
Harbert Discovery Fund, Lp 10 percent owner HARBERT DISCOVERY FUND GP, LLC, 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203
Ian B. Walters director ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022
Mary Tagliaferri director 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO CA 94158
Clemens Peter J Iv 10 percent owner 2383 N. BERRY'S CHAPEL RD., FRANKLIN TN 37069
Rebecca J. Fischer director ENZO BIOCHEM, INC., 527 MADISON AVENUE, NEW YORK NY 10022
Fabian Blank 10 percent owner, other: See Remarks ROEMERSTRASSE 6, BAD BERTRICH 2M 56864
Harbert Management Corp 10 percent owner 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203
Harbert Discovery Co-investment Fund I Gp, Llc 10 percent owner 2100 THIRD AVENUE NORTH, SUITE 600, BIRMINGHAM AL 35203